Aphria engaged in producing and selling medical marijuana through retail sales and wholesale channels. The stock set an all-time high of $8.77 on April 11, but has pulled back along with the rest of the medical–marijuana group. Aphria insiders appear to view the pullback as a buying opportunity. Since April 18, three insiders have spent a combined total of $100,810 picking up shares in the public market. The most recent buyer was chief financial officer Carl Merton who bought 2,000 shares at $5.99.
Ted Dixon is CEO of INK Research which provides insider news and knowledge to investors. For more background on insider reporting in Canada, visit the FAQ section at www.inkresearch.com. Securities referenced in this profile may have already appeared in recent reports distributed to INK subscribers. INK staff may also hold a position in profiled securities.
Graph Footnote:
Chart reflects public-market transactions of common shares or unit trusts by company officers and directors